Lipocine(LPCN) - 2025 Q4 - Annual Results

Financial Position - As of January 31, 2026, Lipocine Inc. had approximately $19 million in cash and cash equivalents[5] - The preliminary cash estimate is subject to completion of financial closing procedures and has not been audited[5] Clinical Trials - The company announced the last patient last visit (LPLV) in its pivotal Phase 3 clinical trial of LPCN for postpartum depression (PPD) on February 18, 2026[6]